Subscriber login: SUBMIT Remember me Home About IPD Our Solutions Our Subscribers Podcast Newsroom Careers Talk to Us COMBINING UNCOMMON EXPERTISE WITH PROPRIETARY DATA TO DRIVE UNIQUE INSIGHT IPD Analytics identifies, projects, and quantifies the impact of competitive-landscape shifts in the pharmaceutical and biologic market to offer: Industry-leading drug life-cycle analysis Clinical, formulary, procurement, and inventory-control insights for payers, providers, and suppliers Brand and generic market impact forecasts Pharmaceutical coding and reimbursement information THE INDUSTRY LEADER AN INDEPENDENT, THIRD-PARTY SOURCE We take data from thousands of sources, combine it with proprietary research, and work to normalize, analyze, and summarize... With a unique team of experts, including: Former Federal Circuit Patent Clerks and Litigators Payor and Provider Clinical Pharmacists Brand and Generic Financial Forecasters from Major Manufacturers PhD Scientists with Pharmacy and Bioscience Backgrounds Team of Researchers and Patent Searchers Utilizing Proprietary Data Aggregation Tools We develop the foundation that powers our solutions: loss-of-exclusivity timing And provide meaningful, tailored insights for specific use cases: Key Litigation Updates & Analysis Critical Headlines & Day-by-day Trial Updates Drug & Disease-Class Reviews Formulary Planning Guidance Loss-of-Exclusivity and Market-Impact Forecasts Analog Library with Accompanying Qualitative Analysis Pipeline-Planning Tools Coding & Reimbursement Insights Drug-Price Tools Scenario Analysis We deliver these insights in multiple, easily consumable formats: To serve stakeholders and institutional investors across the pharmaceutical industry: Platform Email Alerts Direct Consultations Podcast Episodes Reports Data Downloads Manufacturers: Brand Manufacturers Generic Manufacturers Specialty Drug Manufacturers Active Ingredient Manufacturers Learn More Institutional Investors: Investment Managers Hedge Funds Mutual Funds Sovereign Funds Pension Funds THE INDUSTRY LEADER AN INDEPENDENT, THIRD-PARTY SOURCE Since 2002, IPD Analytics has offered solutions that: Deliver compelling insight and unique data assets to solve complex, multi-layered problems Enable efficiency and transparency in an opaque pharmaceutical market Offer a comprehensive look at the past to help predict future market shifts We take data from thousands of sources, combine it with proprietary research, and work to normalize, analyze, and summarize... With a unique team of experts, including: Former Federal Circuit Clerks, Patent Attorneys, and Litigators Payer and Provider Clinical Pharmacists Brand and Generic Financial Forecasters from Major Manufacturers PhD Scientists with Pharmacy and Bioscience Backgrounds Team of Researchers and Patent Searchers Utilizing Proprietary Data-Aggregation Tools We develop the foundation that powers our solutions: loss-of-exclusivity timing and innovative, product-launch tracking And provide meaningful, tailored insights for specific use cases: Drug Litigation Updates & Analysis Critical Headlines & Day-by-Day Trial Updates Drug & Disease-Class Reviews Formulary Planning Guidance Loss-of-Exclusivity and Market-Impact Forecasts Clinical Pipeline Tracking Tools Coding & Reimbursement Solutions Drug-Price and Rebate Monitoring Tools Limited Distribution, Formulary Coverage, Clinical Criteria, and Therapy Cost Analysis Brand, Generic, and Biosimilar Launch Forecasts Budget Impact Models We deliver these insights in multiple, easily consumable formats: To serve stakeholders and institutional investors across the pharmaceutical industry: Online Platform Email Alerts Phone Consultations Podcast Episodes Reports Data Downloads Manufacturers: Brand Manufacturers Generic Manufacturers Specialty-Drug Manufacturers Active-Ingredient Suppliers Payors, Providers, & Suppliers: Payors Health Systems Wholesalers Specialty & Retail Pharmacies Long-Term Care Facilities IDNs GPOs PBMs Institutional Investors: Investment Managers Hedge Funds Mutual Funds Sovereign Funds Pension Funds Private Equity Learn More OUR SOLUTIONS IPD Analytics provides actionable insights to drive decisions. We offer subscription-based access to our proprietary platforms, consultations, real-time email alerts, comprehensive reports, data downloads, podcast episodes, and more. Pharmaceuticals | Biotech | Biosimilars LIFE-CYCLE INSIGHTS Global Life-Cycle Solutions GLOBAL LIFE-CYCLE INSIGHTS Clinical Pharmacy Solutions PAYER & PROVIDER INSIGHTS ACCESS HUB MARKET & FINANCIAL INSIGHTS Market Forecasting Solutions REBATE MONITOR CODING & REIMBURSEMENT BUDGET IMPACT OTHER INDUSTRIES MED-TECH INSIGHTS OUR SUBSCRIBERS IPD Analytics offers tech-enabled solutions to stakeholders across the pharmaceutical landscape. BRAND MANUFACTURERS PAYERS & MANAGED CARE INSTITUTIONAL INVESTORS GENERIC MANUFACTURERS HOSPITALS & HEALTH SYSTEMS OTHER STAKEHOLDERS SUPPLY-CHAIN MEMBERS PODCAST IPD's Drug & Clinical Review: The Premier Podcast for Drug Intelligence and Management Strategy Within each episode, IPD's Executive Clinical Pharmacy Team discusses: Drug pipeline intelligence and clinical strategy surrounding loss of exclusivity, high-cost and complex drugs, formulary planning, and pharmacy and therapeutics management Impactful generic, brand, and biosimilar launches coming down the pipeline Strategies to improve outcomes, lower pharmacy spend, and optimize formulary design Popular questions frequently asked by payers, providers, and manufacturers around the country Podcast samples NEWSROOM FEATURED REPORT FEATURE April 21, 2020 National trends in prescription drug expenditures and projections for 2021 Purpose To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and to predict growth in drug spending in 2021 in the United States, with a focus on the nonfederal hospital and clinic sectors. Methods Historical patterns were assessed by examining data on drug purchases from manufacturers using the IQVIA National Sales Perspectives database. Factors that may influence drug spending in hospitals and clinics in 2021 were reviewed—including new drug approvals, patent expirations, and potential new policies or legislation. Focused analyses were conducted for biosimilars, cancer drugs, generics, coronavirus disease 2019 (COVID-19) pandemic influence, and specialty drugs. For nonfederal hospitals, clinics, and overall (all sectors), estimates of growth of pharmaceutical expenditures in 2021 were based on a combination of quantitative analyses and expert opinion. SEE MORE ARTICLE FEATURE April 21, 2020 Further Dissecting the Launch of Adalimumab Biosimilars in the US As we inch closer to the January 2023 date for the launch of the first US adalimumab biosimilar, industry watchers are more closely scrutinizing which company, if any, will have a competitive advantage in this lucrative marketplace. Just to reset, the series of settlements signed by AbbVie currently puts Amgen’s Amjevita® first to be released, followed by several others according to the schedule we first published in May 2019. A few developments have occurred since then, primarily the subsequent FDA approval of Hulio®, Hadlima®, and Abrilada®. Momenta was acquired by Johnson & Johnson in October 2020 and is no longer a separate entity or operating in the biosimilar business. But Coherus filed for approval in December 2020, and Alvotech and its partner Teva filed in November 2020. Celltrion, which completed its phase 3 trial, is on the verge of filing for approval, and Fresenius Kabi may join the crowd in filing this year as well. SEE MORE ARTICLE FEATURE October 8, 2020 EY Announces Howard Krass founder and CEO of IPD Analytics, LLC as Entrepreneur Of The Year® 2020 Florida Award Winner Ernst & Young LLP (EY US) today announced that Howard Krass of IPD Analytics, LLC was named an Entrepreneur Of The Year® 2020 Florida Award winner. The Entrepreneur Of The Year Awards program is one of the preeminent competitive awards for entrepreneurs and leaders of high-growth companies. Howard was recognized for his excellence in innovation, societal impact, commitment to building a values-based company, financial performance, and overall leadership. Howard Krass was selected by an independent judging panel. The award was announced through the program’s first-ever virtual awards gala, hosted by Deborah Norville, anchor of Inside Edition, on October 8, 2020. To watch the replay, visit the Florida program website. SEE MORE SEE ALL NEWS TALK TO US... How can we help? I would like to hear more about your solutions. I have a media inquiry. I would like to discuss partnership opportunities. Other - I have a general question. arrow&amp;v If you'd like to learn more about one or more of our solutions, please specify: Life-Cycle Insights/Global Life-Cycle Insights Payer & Provider Insights Access Hub Budget Impact Coding & Reimbursement Market & Financial Insights Rebate Monitor I'm interested in all of your solutions. I'm not sure which solutions are right for my organization. Submit LINKS CONTACT & CONNECT Home About IPD Our Solutions Our Subscribers Podcast Newsroom Careers Talk to Us Headquarters: 19950 W Country Club Drive 7th Floor Aventura, FL 33180 Australia Brazil China Germany India Japan Mexico Netherlands Russia South Korea Taiwan info@ipdanalytics.com +1 (305) 662-8515 © 2021 by IPD Analytics | Privacy Policy